TY - JOUR
T1 - Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen
AU - Liu, Tiancheng
AU - Nedrow-Byers, Jessie R.
AU - Hopkins, Mark R.
AU - Berkman, Clifford E.
N1 - Funding Information:
The authors extend their gratitude for technical assistance to G. Helms and W. Hiscox at the WSU Center for NMR Spectroscopy, as well as C. Davitt and V. Lynch-Holm at the WSU Franceschi Microscopy and Imaging Center. This work was supported in part by the Washington State Life Sciences Discovery Fund (LSDF 08-01 2374880) and the National Institutes of Health (5R01CA140617-02).
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, has been becoming an active target for imaging and therapeutic applications for prostate cancer. Recently, the development of its various chemical inhibitor scaffolds has been explored to serve as carriers for therapeutic or diagnostic payloads targeted to PSMA-positive tumor cells. However, there have been few efforts to definitively determine the optimal length of linker between PSMA inhibitor cores and their payload molecules with regard to the affinity to PSMA and in vitro performance. In our present model study, three spacer-length varied fluorescent inhibitors (FAM-CTT-54, FAM-X-CTT-54 and FAM-PEG 8-CTT-54) were synthesized, and further enzymatic inhibition studies displayed linker length-dependent changes in: inhibitory potency (IC 50 = 0.41 nM, 0.35 nM, 1.93 nM), modes of binding (reversible, slowly reversible, irreversible), respectively. Furthermore, cell-labeling imaging revealed the spacer length-related change of fluorescence intensity (FAM-X-CTT-54 > FAM-PEG 8-CTT-54 > FAM-CTT-54). These results suggest that selection of linkers and their lengths will be important considerations in the development of next-generation prostate tumor-targeted imaging probes and therapeutic agents that specifically home to PSMA on tumor cells.
AB - Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, has been becoming an active target for imaging and therapeutic applications for prostate cancer. Recently, the development of its various chemical inhibitor scaffolds has been explored to serve as carriers for therapeutic or diagnostic payloads targeted to PSMA-positive tumor cells. However, there have been few efforts to definitively determine the optimal length of linker between PSMA inhibitor cores and their payload molecules with regard to the affinity to PSMA and in vitro performance. In our present model study, three spacer-length varied fluorescent inhibitors (FAM-CTT-54, FAM-X-CTT-54 and FAM-PEG 8-CTT-54) were synthesized, and further enzymatic inhibition studies displayed linker length-dependent changes in: inhibitory potency (IC 50 = 0.41 nM, 0.35 nM, 1.93 nM), modes of binding (reversible, slowly reversible, irreversible), respectively. Furthermore, cell-labeling imaging revealed the spacer length-related change of fluorescence intensity (FAM-X-CTT-54 > FAM-PEG 8-CTT-54 > FAM-CTT-54). These results suggest that selection of linkers and their lengths will be important considerations in the development of next-generation prostate tumor-targeted imaging probes and therapeutic agents that specifically home to PSMA on tumor cells.
KW - Confocal microscopy
KW - Fluorescein conjugate
KW - PEG linker
KW - PSMA
KW - Tumor-targeting imaging
UR - http://www.scopus.com/inward/record.url?scp=80255122805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80255122805&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2011.09.115
DO - 10.1016/j.bmcl.2011.09.115
M3 - Article
C2 - 22018464
AN - SCOPUS:80255122805
SN - 0960-894X
VL - 21
SP - 7013
EP - 7016
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 23
ER -